Trial Profile
Extension of phase II therapeutic trial with a humanized non-mitogenic CD3 (ChAgly CD3) [otelixizumab] monoclonal antibody in recently diagnosed type 1 diabetic patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 01 Nov 2023 Results reanalyzing trial data to compare the ability of baseline acutely glucose-stimulated proinsulin, C-peptide and PI/CP to predict functional outcome, published in the Diabetes Research and Clinical Practice
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 20 Mar 2008 New trial record.